A5066596081- Parkinson's Disease Mechanisms and Treatments
- Neuroscience and Neuropharmacology Research
- Amyotrophic Lateral Sclerosis Research
- Dementia and Cognitive Impairment Research
- Ion channel regulation and function
- Neurological disorders and treatments
- Cerebral Palsy and Movement Disorders
- Alzheimer's disease research and treatments
- Cardiac electrophysiology and arrhythmias
- Neurogenesis and neuroplasticity mechanisms
- RNA regulation and disease
- Neurological diseases and metabolism
- Pluripotent Stem Cells Research
- Receptor Mechanisms and Signaling
- Autism Spectrum Disorder Research
- Cancer-related cognitive impairment studies
- Enzyme Production and Characterization
- Health, Environment, Cognitive Aging
- Health Systems, Economic Evaluations, Quality of Life
- Genetic Associations and Epidemiology
- 3D Printing in Biomedical Research
- Studies on Chitinases and Chitosanases
- Neurological Disease Mechanisms and Treatments
- Cognitive Functions and Memory
- Nuclear Receptors and Signaling
University of Saskatchewan
2021
Saskatoon Medical Imaging
2021
National Institutes of Health
2012-2020
National Institute of Neurological Disorders and Stroke
2012-2020
Chan Zuckerberg Initiative (United States)
2019
Mayo Clinic in Florida
2014-2017
Rush University Medical Center
2017
Harvard University
2014
Massachusetts General Hospital
2014
University of California, San Francisco
2014
Our understanding of the molecular mechanisms many neurological disorders has been greatly enhanced by discovery mutations in genes linked to familial forms these diseases. These have facilitated generation cell and animal models that can be used understand underlying pathology. Recently, there a surge interest use patient-derived cells, due development induced pluripotent stem cells their subsequent differentiation into neurons glia. Access patient lines carrying relevant is limiting factor...
ABSTRACT Objective: Examine relationships among neurodegenerative biomarkers and PD motor nonmotor symptoms. Background: CSF alpha‐synuclein is decreased in versus healthy controls, but whether plasma saliva differentiate these groups controversial. Correlations of biofluids (CSF, plasma, saliva) or (eg, beta‐amyloid, tau [total, phosphorylated]) are not fully understood. The with clinical features remain unclear. Methods: BioFIND, a cross‐sectional, observational study, examines biomarker...
Abstract We performed the largest genome-wide association study of PD to date, involving analysis 7.8M SNPs in 37.7K cases, 18.6K UK Biobank proxy-cases, and 1.4M controls. identified 90 independent significant signals across 78 loci, including 38 risk 37 novel loci. These variants explained 26-36% heritable PD. Tests causality within a Mendelian randomization framework putatively causal genes for 70 signals. Tissue expression enrichment suggested that signatures loci were heavily...
Neuroprotection for Parkinson's disease (PD) remains elusive. Biomarkers hold the promise of removing roadblocks to therapy development. The National Institute Neurological Disorders and Stroke has therefore established Disease Program promote discovery PD biomarkers use in phase II III clinical trials.Using a novel consortium design, Biomarker is focused on development laboratory-based diagnosis, progression, prognosis. Standardized operating procedures pooled reference samples were created...
Abstract The National Institutes of Health has partnered with the US Food and Drug Administration Defense Advanced Research Projects Agency to accelerate development human microphysiological systems (MPS) that address challenges faced in predictive toxicity assessment efficacy analysis new molecular entities during preclinical phase drug development. Use MPS could provide better models for predicting clinical trials. It is also anticipated improvements toxicities early process through use or...
Galectins are pleiotropic carbohydrate-binding lectins involved in inflammation, growth/differentiation, and tissue remodeling. The functional role of galectins amyotrophic lateral sclerosis (ALS) is unknown. Expression studies revealed increases galectin-1 mRNA protein spinal cords from SOD1(G93A) mice, galectin-3 -9 mRNAs proteins both mice sporadic ALS patients. As the increase appeared early presymptomatic stages increased progressively through to end stage disease mouse, it was selected...
Glutamate is the predominant excitatory neurotransmitter in CNS, and it removed from synaptic cleft by sodium-dependent glutamate transport activity. transporter-1 (GLT-1) expressed predominantly astroglial cells responsible for largest proportion of adult forebrain. In present study, we demonstrate ability endogenous recombinant GLT-1 to form clusters astrocytic processes characterize mobility physiological importance these regulation activity presence or absence neurons. At distal end C6...
Deficits in working memory and executive functions are now considered among the most reliable endophenotypes for schizophrenia. To determine whether cognitive deficits exist mouse models of disease, authors trained heterozygous reeler (+/rl) mice on a series visual discriminations similar to those used test abilities primates. These resemble schizophrenia patients that both have reduced levels reelin protein altered gamma aminobutyric acid neurotransmission prefrontal cortex. The +/rl showed...
The Extracellular RNA (exRNA) Communication Consortium, funded as an initiative of the NIH Common Fund, represents a consortium investigators assembled to address critical issues in exRNA research arena. overarching goal is generate multi‐component community resource for sharing fundamental scientific discoveries, protocols, and innovative tools technologies. key initiatives include (a) generating reference catalogue exRNAs present body fluids normal healthy individuals that would facilitate...
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders Stroke Disease Biomarker Program (PDBP) other mechanisms, no single PD marker or set ready use. Here we discuss current state biomarker discovery platforms relevant to PDBP. We role PDBP in identification present guidelines facilitate their development. These...
ABSTRACT Background Identifying PD‐specific biomarkers in biofluids will greatly aid diagnosis, monitoring progression, and therapeutic interventions. PD have been limited by poor discriminatory power, partly driven heterogeneity of the disease, variability collection protocols, focus on de novo, unmedicated patients. Thus, a platform for biomarker discovery validation well‐characterized, clinically typical, moderate to advanced cohorts is critically needed. Methods BioFIND (Fox...
Frontotemporal lobar degeneration (FTLD) is the most common form of dementia for those under 60 years age. Increasing numbers therapeutics targeting FTLD syndromes are being developed.